The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.
The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.
复制标题
DOI：
10.3346/jkms.2006.21.1.40
复制
发表时间：
2006-02
影响因子：
4.5
通讯作者：
Hyun MS
中科院分区：
文献类型：
--
作者：
Kim MK;Lee JL;Cho HS;Bae SH;Ryoo HM;Lee KH;Hyun MS
TNF-α介导的造血细胞凋亡被认为是导致骨髓增生异常综合征（MDS）中观察到的无效造血的原因。已证实，喷替福林（P）和环丙沙星（C）的组合可降低血清TNF-α水平，并且P和C与地塞米松（D）的早期试验为MDS患者提供了良好的缓解。本研究的目的是评估患有MDS的患者对PCD治疗的血液学反应。完成至少12周治疗的25例患者中有21例可评价治疗疗效。基线时，患者的中位年龄为60岁（范围：18-75岁）。根据WHO分类，诊断包括：RA（n=5）、RCMD（n=10）、RARS（n=1）、RCMD/RS（n=1）、RAEB（3）和CMML（n=1）。11例患者（52%）至少有单系缓解。3例患者（11%）显示三系血细胞减少改善。FAB亚型之间的应答率没有差异。中位缓解时间为4周（范围：2-12周），有趣的是，11例缓解患者中有9例在中位177天（范围：78-634天）内未复发。这些初步结果表明，PCD的抗细胞因子治疗是MDS患者的有效且耐受性良好的姑息治疗。
TNF-α mediated apoptosis of the hematopoietic cells has been thought to contribute to the ineffective hematopoiesis observed in myelodysplastic syndrome (MDS). The combination of pentoxifylline (P) and ciprofloxacin (C) has been shown to reduce the serum levels of TNF-α, and an earlier trial of P and C with dexamethasone (D) provided good palliation for patients with MDS. The purpose of this study is to assess the hematologic response to PCD therapy for patients suffering with MDS. 21 of 25 patients who completed at least of 12 weeks of treatment were evaluable for the treatment efficacy. At baseline, the patient's median age was 60 yr (range: 18-75 yr). The diagnoses according to WHO classification included: RA (n=5), RCMD (n=10), RARS (n=1), RCMD/RS (n=1), RAEB (3), and CMML (n=1). 11 patients (52%) had at least single lineage response. 3 patients (11%) showed improvement of triple lineage cytopenia. There were no differences in the response rates between the FAB subtypes. The median time to response was 4 weeks (range: 2-12 weeks), and it is interesting that 9 of 11 patients who had a response remained without relapse for a median of 177 days (range: 78-634 days). These preliminary results indicate that anti-cytokine therapy with PCD is an effective and well tolerated palliative treatment for patients with MDS.
登录
查看更多内容
影响因子：
20.3
作者：
List, AF;Brasfield, F;Capizzi, R
通讯作者：
Capizzi, R
影响因子：
6.5
作者：
Maciejewski, JP;Ristiano, AM;Young, NS
通讯作者：
Young, NS
影响因子：
20.3
作者：
Raza, A;Meyer, P;Zeldis, J
通讯作者：
Zeldis, J
影响因子：
20.3
作者：
Greenberg, P;Cox, C;Bennett, J
通讯作者：
Bennett, J
影响因子：
20.3
作者：
Raza, A;Qawi, H;Huang, RW
通讯作者：
Huang, RW